BeStock  
Stocks › Cancer Research › BIIB

Biogen BIIB

US equityMarket cap rank #410Cancer Research
$225.08 −$0.81 (-0.36%)
Market open · Oct 1, 1:20 pm ET · After hours $225.88 0.00%
Open$225.50
Prev close$225.88
Day range$224.19 – $228.31
Volume599.0K
Market cap$33.26B
P/E (TTM)40.0
Dividend yield–

Valuation

Multiples measured against the stock's own five-year history

Price / earnings40.1x
CheapRich

Near the top of its 5-year range · 100th percentile, 5-year average 19.1x

#2376 of 2977 stocks by PE (1 = cheapest)

Price / book1.8x
CheapRich

Below its usual level · 40th percentile, 5-year average 2.2x

#2687 of 5307 stocks by PB (1 = cheapest)

Price / sales3.3x
CheapRich

Above its usual level · 65th percentile, 5-year average 3.0x

#3274 of 5144 stocks by PS (1 = cheapest)

Morningstar fair value estimate

Fair value$221.58
Price vs. fair value+1.6%Close to the estimate
Star rating★★★☆☆
Economic moatNarrow
UncertaintyMedium
MultipleCurrentForward5y averagePercentile vs. own historyIndustry rank
PB 1.77 – 2.19 40% (cheaper than usual) #2687 of 5307 (1 = cheapest)
PE 40.12 25.48 19.14 100% (pricier than usual) #2376 of 2977 (1 = cheapest)
PS 3.33 3.18 3.04 65% (pricier than usual) #3274 of 5144 (1 = cheapest)

Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.

Morningstar view

Star rating★★★
Fair value estimate$221.58
Economic moatNarrow
UncertaintyMedium

Discussion

No comments yet — be the first to weigh in on BIIB.

Leave a comment

Scroll to Top